Barclays PLC Arcturus Therapeutics Holdings Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Barclays PLC holds 67,415 shares of ARCT stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,415

Previous 67,415 -0.0%

Holding current value

$1.21 Million

Previous $1.56 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$18.08 - $25.38 $432,365 - $606,937	23,914 Added 54.97%	67,415 $1.56 Million
Q2 2024 Aug 14, 2024	BUY	$24.35 - $44.39 $188,882 - $344,333	7,757 Added 21.7%	43,501 $1.06 Million
Q1 2024 May 15, 2024	SELL	$31.23 - $42.99 $1.52 Million - $2.1 Million	-48,765 Reduced 57.7%	35,744 $1.21 Million
Q4 2023 Feb 15, 2024	SELL	$17.71 - $32.97 $495,136 - $921,775	-27,958 Reduced 24.86%	84,509 $2.66 Million
Q3 2023 Nov 07, 2023	BUY	$25.44 - $37.35 $384,449 - $564,433	15,112 Added 15.52%	112,467 $2.87 Million
Q2 2023 Aug 03, 2023	BUY	$23.94 - $32.36 $261,472 - $353,435	10,922 Added 12.64%	97,355 $2.79 Million
Q1 2023 May 04, 2023	SELL	$14.72 - $23.97 $324,767 - $528,850	-22,063 Reduced 20.34%	86,433 $2.07 Million
Q4 2022 Feb 13, 2023	SELL	$14.14 - $23.06 $173,172 - $282,415	-12,247 Reduced 10.14%	108,496 $1.84 Million
Q3 2022 Nov 03, 2022	BUY	$13.05 - $22.13 $993,183 - $1.68 Million	76,106 Added 170.5%	120,743 $1.79 Million
Q2 2022 Aug 12, 2022	BUY	$12.26 - $31.17 $503,358 - $1.28 Million	41,057 Added 1146.84%	44,637 $702,000
Q1 2022 May 16, 2022	SELL	$17.64 - $39.57 $388,838 - $872,241	-22,043 Reduced 86.03%	3,580 $96,000
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $486,529 - $676,588	14,226 Added 124.82%	25,623 $949,000
Q3 2021 Nov 09, 2021	BUY	$27.88 - $58.25 $221,924 - $463,670	7,960 Added 231.6%	11,397 $544,000
Q2 2021 Aug 13, 2021	SELL	$25.79 - $42.11 $791,598 - $1.29 Million	-30,694 Reduced 89.93%	3,437 $117,000
Q1 2021 May 13, 2021	SELL	$38.75 - $86.92 $1.61 Million - $3.62 Million	-41,675 Reduced 54.98%	34,131 $1.41 Million
Q4 2020 Feb 11, 2021	BUY	$34.61 - $123.66 $2.32 Million - $8.3 Million	67,142 Added 774.95%	75,806 $3.29 Million
Q3 2020 Nov 12, 2020	SELL	$37.49 - $63.19 $861,295 - $1.45 Million	-22,974 Reduced 72.62%	8,664 $371,000
Q2 2020 Aug 12, 2020	BUY	$12.66 - $58.27 $366,684 - $1.69 Million	28,964 Added 1083.17%	31,638 $1.48 Million
Q1 2020 May 13, 2020	BUY	$9.31 - $18.26 $21,636 - $42,436	2,324 Added 664.0%	2,674 $36,000
Q4 2019 Feb 10, 2020	BUY	$8.93 - $12.41 $2,482 - $3,449	278 Added 386.11%	350 $4,000
Q3 2019 Nov 14, 2019	BUY	$8.8 - $14.5 $633 - $1,044	72 New	72 $1,000

Others Institutions Holding ARCT

# of Institutions

178

Shares Held

25.6M

Call Options Held

195K

Put Options Held

133K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $478M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account